Literature DB >> 16870775

Novel real-time monitoring system for human cytomegalovirus-infected cells in vitro that uses a green fluorescent protein-PML-expressing cell line.

T Ueno1, Y Eizuru, H Katano, T Kurata, T Sata, S Irie, K Ogawa-Goto.   

Abstract

Promyelocytic leukemia (PML) bodies are discrete nuclear foci that are intimately associated with many DNA viruses. In human cytomegalovirus (HCMV) infection, the IE1 (for "immediate-early 1") protein has a marked effect on PML bodies via de-SUMOylation of PML protein. Here, we report a novel real-time monitoring system for HCMV-infected cells using a newly established cell line (SE/15) that stably expresses green fluorescent protein (GFP)-PML protein. In SE/15 cells, HCMV infection causes specific and efficient dispersion of GFP-PML bodies in an IE1-dependent manner, allowing the infected cells to be monitored by fluorescence microscopy without immunostaining. Since a specific change in the detergent solubility of GFP-PML occurs upon infection, the infected cells can be quantified by GFP fluorescence measurement after extraction. With this assay, the inhibitory effects of heparin and neutralizing antibodies were determined in small-scale cultures, indicating its usefulness for screening inhibitory reagents for laboratory virus strains. Furthermore, we established a sensitive imaging assay by counting the number of nuclei containing dispersed GFP-PML, which is applicable for titration of slow-growing clinical isolates. In all strains tested, the virus titers estimated by the GFP-PML imaging assay were well correlated with the plaque-forming cell numbers determined in human embryonic lung cells. Coculture of SE/15 cells and HCMV-infected fibroblasts permitted a rapid and reliable method for estimating the 50% inhibitory concentration values of drugs for clinical isolates in susceptibility testing. Taken together, these results demonstrate the development of a rapid, sensitive, quantitative, and specific detection system for HCMV-infected cells involving a simple procedure that can be used for titration of low-titer clinical isolates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870775      PMCID: PMC1538688          DOI: 10.1128/AAC.01641-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.

Authors:  M L Landry; S Stanat; K Biron; D Brambilla; W Britt; J Jokela; S Chou; W L Drew; A Erice; B Gilliam; N Lurain; J Manischewitz; R Miner; M Nokta; P Reichelderfer; S Spector; A Weinberg; B Yen-Lieberman; C Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients.

Authors:  Raymund R Razonable; Carlos V Paya; Thomas F Smith
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 3.  Cytomegalovirus (CMV) resistance to antivirals.

Authors:  W L Drew; C V Paya; V Emery
Journal:  Am J Transplant       Date:  2001-11       Impact factor: 8.086

Review 4.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E.

Authors:  Osamu Ijichi; Detlef Michel; Thomas Mertens; Koichiro Miyata; Yoshito Eizuru
Journal:  Antiviral Res       Date:  2002-02       Impact factor: 5.970

Review 6.  Review: properties and assembly mechanisms of ND10, PML bodies, or PODs.

Authors:  G G Maul; D Negorev; P Bell; A M Ishov
Journal:  J Struct Biol       Date:  2000-04       Impact factor: 2.867

7.  Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen.

Authors:  C A Gleaves; T F Smith; E A Shuster; G R Pearson
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

8.  Human-herpesvirus-8-encoded K8 protein colocalizes with the promyelocytic leukemia protein (PML) bodies and recruits p53 to the PML bodies.

Authors:  H Katano; K Ogawa-Goto; H Hasegawa; T Kurata; T Sata
Journal:  Virology       Date:  2001-08-01       Impact factor: 3.616

9.  An endoplasmic reticulum protein, p180, is highly expressed in human cytomegalovirus-permissive cells and interacts with the tegument protein encoded by UL48.

Authors:  K Ogawa-Goto; S Irie; A Omori; Y Miura; H Katano; H Hasegawa; T Kurata; T Sata; Y Arao
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 10.  Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact.

Authors:  Fausto Baldanti; Giuseppe Gerna
Journal:  J Antimicrob Chemother       Date:  2003-07-29       Impact factor: 5.790

View more
  3 in total

1.  Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay.

Authors:  Yoshiko Fukui; Keiko Shindoh; Yumiko Yamamoto; Shin Koyano; Isao Kosugi; Toyofumi Yamaguchi; Ichiro Kurane; Naoki Inoue
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

2.  Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness.

Authors:  Meike Chevillotte; Axel Schubert; Thomas Mertens; Jens von Einem
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

3.  A Luciferase Gene Driven by an Alphaherpesviral Promoter Also Responds to Immediate Early Antigens of the Betaherpesvirus HCMV, Allowing Comparative Analyses of Different Human Herpesviruses in One Reporter Cell Line.

Authors:  Anna Katharina Maier; Raimund Jung; Clarissa Villinger; Axel Schubert; Paul Walther; Christian Sinzger; Diana Lieber
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.